Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
Carol J. Swallow(University Health Network), Dimitri Tzanis(Institut Curie), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Hayden Snow(Peter MacCallum Cancer Centre), Myles Smith(Royal Marsden NHS Foundation Trust), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Anant Desai(NIHR Surgical Reconstruction and Microbiology Research Centre), Thomas F. DeLaney(Massachusetts General Hospital), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Toufik Bouhadiba(Institut Curie), Kenneth Cardona(Emory University), Rebecca A. Gladdy(Princess Margaret Cancer Centre), Rick L. Haas(Leiden University Medical Center), John E. Mullinax(Moffitt Cancer Center), Deanna Ng(Mount Sinai Hospital), Robin L. Jones(Institute of Cancer Research), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), D. Strauß(Royal Marsden Hospital), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Winan J. van Houdt(Diakonessenhuis hospital), Markus Albertsmeier(LMU Klinikum), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Jae Berm Park(Samsung Medical Center), Christina L. Roland(The University of Texas MD Anderson Cancer Center), Eberhard Stoeckle(Institut Bergonié), Andrew Hayes(Royal Marsden NHS Foundation Trust), Ricardo González(Moffitt Cancer Center), David Gyorki(The University of Melbourne), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology)
Cited by 243
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k